Aired 2 months ago 57:52
Amanpour: Ellie Singer, Anna McNeil, David Spiegelhalter and Jonathan Metzl
From the news
Aired 1 year ago 34:14
Episode 19: Revolutionary Thinking Required
In this episode we're exploring ways to jumpstart the immune system so that subsequent therapies can be more effective, especially in cold non-inflamed tumours. It is becoming increasingly clear that people with pre-existing immunity respond better to cancer immunotherapies. - What is it, why does it matter and how do we measure it? - What types of therapeutic approaches might be helpful for boosting it? In this show, you'll hear from some new and familiar expert voices alike: - Dr Jérôme Galon (INSERM) discusses the concept of pre-existing immunity and why it matters - Dr Carlos Paya (Immune Design) explains how a cancer testis vaccine can boost immunity in cold tumours such as sarcomas; - Dr Mario Sznol (Yale) talks about cytokines and why they may be an important factor to consider; - Drs Adi Diab (MD Anderson) and Jonathan Zalevsky (Nektar) discuss an immune agonist that may be useful in stimulating key immune cells and act synergistically with checkpoint blockade ; - Drs Friedrich Finckenstein, Dietmar Berger and Dan Chen (Roche Genentech) explain the concept of T cell bispecifics and describe what they found when a novel bispecific was used in a cold tumour such as colon cancer. You can find more information about the topics discussed in the show notes on https://noveltargets.com. All the interviews were first published on https://biotechstrategyblog.com. Copyright © 2017 Blue Ice Publishing LLC. All Rights Reserved.
Aired 1 year ago 36:23
Episode 23: Modulating the Signal
In this episode we take a look a look at how cytokines can be employed to modulate the tumour microenvironment in favourable ways. You'll hear various perspectives from numerous academic and industry experts who are active in research in this field, including Dr Mario Sznol (Yale), Dr James Gulley (NCI), Dr Adi Diab (MD Anderson), Dr Jonathan Zalevsky (Nektar Therapeutics), Dr Sanjeev Mariathasan (Genentech), Prof Tom Powles (Barts Cancer Institute), Dr Kunle Odunsi (Roswell Park), and Dr Renier Brentjens (Memorial Sloan Kettering). Some important topics that we will cover: - What are cytokines? - Why do they matter? - The good and bad effects they can induce on the tumour microenvironment (TME) - Interleukins - Transforming Growth Factor beta (TGFβ) - The increasingly important role for reverse translation research in helping to understand what's going on in the TME in order to improve rational future immuno-oncology (IO) combination approaches - Can we determine differences in responders and non-responders? - Novel approaches in clinical development, including CAR T cell therapies in solid tumours, and why they are different from previous approaches that were either too toxic or ineffective You can find more detailed information about the topics discussed in the show notes on https://noveltargets.com. Most of the interviews were conducted at recent AACR and ASCO meetings in 2018 and full transcripts of the individual interviews can be found on https://biotechstrategyblog.com. The music is by violinist and composer David Schulman. Listen to more at http://www.quietlifemotel.com © 2018 Blue Ice Publishing LLC. All Rights Reserved.
Aired 2 months ago 66:12
The Evolutionary Origins of a Good Society (Nicholas Christakis Interview)
Yeah. Joining me today as a sociologist physician professor gale university and author of the new book blueprint, the evolutionary ...
The Rubin Report